Large hospitals with pancreatic surgery centers are the first choice for the treatment of pancreatic cancer patients. A large number of clinical studies at home and abroad have shown that experienced pancreatic surgery specialists have a significantly higher rate of correct diagnosis and successful surgical treatment of pancreatic cancer than non-specialists. The Department of General Surgery of Changhai Hospital (Pancreatic, Spleen, Hepatobiliary) was established in 1989 as a specialized group of pancreatic surgery. In the past 20 years, it now performs more than 500 cases of various pancreatic surgeries annually, and has accumulated rich experience in the external treatment of pancreatic cancer, and is capable of providing specialized and standardized diagnosis and treatment for patients with suspected pancreatic cancer. Ultrasound is easy, economical, non-invasive and repeatable, and is the preferred means of screening patients with suspected pancreatic cancer in clinical practice. Thin-section, dynamic, enhanced CT scans have a positive rate of about 90% and are the most commonly used method to diagnose pancreatic cancer. Magnetic resonance cholangiopancreatography (MRCP), retrograde cholangiopancreatography (ERCP), and endoscopic ultrasound (EUS) can also provide important diagnostic clues. Positron emission tomography (PET) can detect lymph nodes and small liver metastases that cannot be detected by CT and EUS, and differentiate them from chronic pancreatitis. The normal value of CA19-9 is less than 37 U/L. All patients with suspected pancreatic cancer should have their blood CA19-9 checked. It is worth noting that (1) the absence of elevated CA19-9 does not mean the absence of pancreatic cancer, because about 25% of pancreatic cancer patients do not have high CA19-9; (2) The diagnostic value of CA19-9 should be considered together with the imaging results.